Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?

Biochim Biophys Acta. 2015 Jan;1855(1):43-9. doi: 10.1016/j.bbcan.2014.11.004. Epub 2014 Nov 26.

Abstract

Pancreatic cancer is one of the most aggressive solid malignancies. This aggressiveness is partly attributable to extensive local tumor invasion and early systemic dissemination as well as resistance to chemotherapy. Epithelial-mesenchymal transition (EMT) plays fundamental roles in embryonic development and in the differentiation of normal tissues and organs. EMT also plays critical roles in tumor formation, dissemination and drug resistance in pancreatic cancer. Emerging data suggest that inhibiting EMT may reverse the EMT phenotype and enhance the efficacy of chemotherapeutic agents against pancreatic cancer cells. Thus, an understanding of the molecular biology of EMT in pancreatic cancer may provide insights into the mechanisms of tumor invasion and metastatic progression and facilitate the development of alternative therapeutic approaches to improve the treatment outcomes for patients suffering from pancreatic cancer.

Keywords: Epithelial–mesenchymal transition; Metastasis; Pancreatic cancer; Prognosis; Therapy; Tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autophagy / physiology
  • Cell Communication
  • Cell Transformation, Neoplastic* / pathology
  • Epithelial-Mesenchymal Transition / physiology*
  • Humans
  • MicroRNAs / physiology
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / pathology*
  • Pancreatic Neoplasms / therapy
  • Prognosis
  • Stromal Cells / physiology

Substances

  • MicroRNAs